Kapur, Payal

Targeting renal cell carcinoma with a HIF-2 antagonist

Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 709

A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer

Chang, K.-H., Li, R., Kuri, B., Lotan, Y., Roehrborn, C. G., Liu, J., Vessella, R., Nelson, P. S., Kapur, P., Guo, X., et al. (2013) · Cell

Prostate Cancer Treatment and ResearchCancer, Lipids, and Metabolism

Cited by 312

Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo

Courtney, K. D., Bezwada, D., Mashimo, T., Pichumani, K., Vemireddy, V., Funk, A. M., Wimberly, J., McNeil, S. S., Kapur, P., Lotan, Y., et al. (2018) · Cell Metabolism

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 280

HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma

Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., et al. (2020) · Clinical Cancer Research

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 188

Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.

Elias, R., Yan, F., Singla, N., Levonyack, N., Formella, J., Christie, A., Kapur, P., Bowman, A. I., Hammers, H. J., Hannan, R., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 48